Chi Saint Joseph Cancer Care Center - London

CLIA Laboratory Citation Details

2
Total Citations
7
Total Deficiencyies
5
Unique D-Tags
CMS Certification Number 18D1053655
Address 165 London Mountain View Drive, London, KY, 40741
City London
State KY
Zip Code40741
Phone606 330-7900
Lab DirectorSTANLEY DAVIS

Citation History (2 surveys)

Survey - December 12, 2022

Survey Type: Standard

Survey Event ID: WN4X11

Deficiency Tags: D0000 D5209 D5209 D5775 D5775

Summary:

Summary Statement of Deficiencies D0000 A recertification survey was conducted on 12/12/2022 and the facility was found not to be in substantial compliance with the laboratory requirements at 42 CFR Part 493, with deficiencies cited. D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on interview, record review, and review of the facility's policies, it was determined that the facility failed to follow its written policies for competency assessment for two (2) of seven (7) testing personnel (TP #6 and TP #7). The findings include: Review of the facility's policy titled, "Competency Assessment", effective 06 /2015 and last reviewed 02/2022, revealed a comprehensive competency assessment is conducted upon all new hires in the laboratory prior to starting patient testing and prior to reporting results. Further review revealed all personnel are evaluated for competency, as it is an "ongoing process and is occurring continuously throughout the year by the administrative laboratory manager and designated personnel who meet the requirements for Moderately Complex testing general supervisors, technical consultants or directors". Review of a 2020 proficiency testing attestation statement, dated 11/19/2020, compared against the personnel competency assessment records, revealed no documentation of competency assessments for TP #6 and TP #7. Review of a 2021 proficiency testing attestation statement, dated 07/30/2021, compared against the personnel competency assessment records, revealed no documentation of competency assessment for TP #7. Interview with the Laboratory Director, on 12/12 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- /2022 at 12:30 PM, revealed he examined the proficiency testing attestation forms and competency assessment records referenced above, and confirmed there were no competency assessments performed for TP #6 and TP #7. D5775 COMPARISON OF TEST RESULTS CFR(s): 493.1281(a)(c) (a) If a laboratory performs the same test using different methodologies or instruments, or performs the same test at multiple testing sites, the laboratory must have a system that twice a year evaluates and defines the relationship between test results using the different methodologies, instruments, or testing sites. (c) The laboratory must document all test result comparison activities. This STANDARD is not met as evidenced by: Based on observation, interview, and record review, it was determined the facility failed to implement a system to evaluate the relationship between tests performed at the facility, and at the main hospital, to ensure consistent results were produced for patients who came to the facility for weekly chemotherapy treatments. The findings include: A review of the facility's procedure manual, reviewed on 01/2022, revealed there was no documented procedure regarding performance of the required comparison tests. A concurrent observation and interview with the Laboratory Director (LD), on 12/12/2022 at 12:45 PM, revealed that since 10/25/2022, when a new electronic medical record (EMR) system was implemented, testing could only be performed at the facility when either the LD or other laboratory testing personnel (TP) were on site. Further interview revealed the LD and TP were the only authorized users for the new EMR, which was interfaced to the laboratory instrument. Continued interview with the LD revealed that patients who came to be treated at the facility when there was no authorized TP on site would have their blood specimens drawn and sent to the main hospital laboratory for testing. Patients that came to the facility for their weekly chemotherapy treatments could be tested at either location. The surveyor observed the hematology instrument in use at the facility was a Coulter ACTDiff2. Per the LD, the hematology instrument in use at the hospital was a Sysmex. When asked whether the laboratory performed comparisons between the Coulter ACTDiff2 instrument in use at the facility and the Sysmex instrument in use at the hospital, the LD stated no. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - September 14, 2021

Survey Type: Special

Survey Event ID: 9YT811

Deficiency Tags: D2016 D2131

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on the desk review of hematology proficiency testing results from the American Proficiency Institute (API), the laboratory failed to successfully participate in two (2) hematology testing events for Cell ID or WBC diff. See D2131. D2131 HEMATOLOGY CFR(s): 493.851(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- unsuccessful performance. This STANDARD is not met as evidenced by: Based on the desk review of proficiency testing results from the American Proficiency Institute (API) on 09/14/2021, the laboratory failed to achieve satisfactory overall Hematology testing event scores in two (2) testing events. Findings include: 1. The laboratory failed to achieve a satisfactory score for the Cell ID or WBC Diff in the third (3rd) event of 2020 with a score of seventy-three percent (73%). 2. The laboratory failed to achieve a satisfactory score for the Cell ID or WBC Diff in the second (2nd) event of 2021 with a score of zero Percent (0%). -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access